These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 10744049)

  • 1. HeLa cell transformants overproducing mouse metallothionein show in vivo resistance to cis-platinum in nude mice.
    Toyoda H; Mizushima T; Satoh M; Iizuka N; Nomoto A; Chiba H; Mita M; Naganuma A; Himeno S; Imura N
    Jpn J Cancer Res; 2000 Jan; 91(1):91-8. PubMed ID: 10744049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumours from a cell strain with a high content of metallothionein show enhanced resistance against cis-dichlorodiammineplatinum.
    Endresen L; Schjerven L; Rugstad HE
    Acta Pharmacol Toxicol (Copenh); 1984 Sep; 55(3):183-7. PubMed ID: 6542297
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protective function of metallothionein against certain anticancer agents.
    Endresen L; Rugstad HE
    Experientia Suppl; 1987; 52():595-602. PubMed ID: 2959550
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metallothionein-like proteins and cell resistance to cis-dichlorodiammineplatinum(II) in L1210 cells.
    Farnworth P; Hillcoat B; Roos I
    Cancer Chemother Pharmacol; 1990; 25(6):411-7. PubMed ID: 2311168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Basal and zinc-induced metallothionein in resistance to cadmium, cisplatin, zinc, and tertbutyl hydroperoxide: studies using MT knockout and antisense-downregulated MT in mammalian cells.
    Kennette W; Collins OM; Zalups RK; Koropatnick J
    Toxicol Sci; 2005 Dec; 88(2):602-13. PubMed ID: 16150881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reversal of acquired cisplatin resistance by modulation of metallothionein in transplanted murine tumors.
    Saga Y; Hashimoto H; Yachiku S; Iwata T; Tokumitsu M
    Int J Urol; 2004 Jun; 11(6):407-15. PubMed ID: 15157211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Altered cisplatin and cadmium resistance and cell survival in Chinese hamster ovary cells expressing mouse metallothionein.
    Koropatnick J; Pearson J
    Mol Pharmacol; 1993 Jul; 44(1):44-50. PubMed ID: 8341278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renal toxicity caused by cisplatinum in glutathione-depleted metallothionein-null mice.
    Satoh M; Shimada A; Zhang B; Tohyama C
    Biochem Pharmacol; 2000 Dec; 60(11):1729-34. PubMed ID: 11077056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effects of the expression of mouse metallothionein-I gene in human HeLa cell line on drug resistance].
    Li X; Lü W; Yin S; Li L
    Wei Sheng Yan Jiu; 2000 Jul; 29(4):199-201. PubMed ID: 12520915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo and in vitro binding of platinum to metallothionein.
    Zelazowski AJ; Garvey JS; Hoeschele JD
    Arch Biochem Biophys; 1984 Feb; 229(1):246-52. PubMed ID: 6538400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulation of both cisplatin nephrotoxicity and drug resistance in murine bladder tumor by controlling metallothionein synthesis.
    Satoh M; Kloth DM; Kadhim SA; Chin JL; Naganuma A; Imura N; Cherian MG
    Cancer Res; 1993 Apr; 53(8):1829-32. PubMed ID: 8467502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interaction of cis- and trans-diamminedichloroplatinum with metallothionein in vivo.
    Zhang B; Huang H; Tang W
    J Inorg Biochem; 1995 Apr; 58(1):1-8. PubMed ID: 7738537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Metallothionein as a resistance factor for antitumor drugs].
    Imura N; Naganuma A; Satoh M
    Gan To Kagaku Ryoho; 1989 Mar; 16(3 Pt 2):599-604. PubMed ID: 2705789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimal administration schedule of cisplatin for bladder tumor with minimal induction of metallothionein.
    Kondo Y; Yamagata K; Satoh M; Himeno S; Imura N; Nishimura T
    J Urol; 2003 Dec; 170(6 Pt 1):2467-70. PubMed ID: 14634452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Arsenic accumulation decreased in metallothionein null Cisplatin-resistant cell lines.
    Suzuki T; Ohata S; Togawa T; Himeno S; Tanabe S
    J Toxicol Sci; 2007 Aug; 32(3):321-8. PubMed ID: 17785947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapid emergence of acquired cis-diamminedichloroplatinum(II) resistance in an in vivo model of human ovarian carcinoma.
    Andrews PA; Jones JA; Varki NM; Howell SB
    Cancer Commun; 1990; 2(2):93-100. PubMed ID: 2372473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metallothionein-mediated cisplatin resistance in human ovarian carcinoma cells.
    Andrews PA; Murphy MP; Howell SB
    Cancer Chemother Pharmacol; 1987; 19(2):149-54. PubMed ID: 3568272
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Establishment and biological characteristics of a platinum-resistance nude mouse model in epithelial ovarian cancer].
    Shi L; Yu H; Zhang W; Li L; Wang Q
    Zhonghua Fu Chan Ke Za Zhi; 2014 Jul; 49(7):523-30. PubMed ID: 25327735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metallothionein induction in mouse tissues by cis-dichlorodiammineplatinum(II) and its hydrolysis products.
    Farnworth PG; Hillcoat BL; Roos IA
    Chem Biol Interact; 1989; 69(4):319-32. PubMed ID: 2731304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of cisplatin-resistance by RNA interference targeting metallothionein using reducible oligo-peptoplex.
    Lee JH; Chae JW; Kim JK; Kim HJ; Chung JY; Kim YH
    J Control Release; 2015 Oct; 215():82-90. PubMed ID: 26210439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.